Targeting invadopodia to block breast cancer metastasis

Mark A Eckert; Jing Yang

doi:10.18632/oncotarget.301

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Perspectives:

Targeting invadopodia to block breast cancer metastasis

Mark A Eckert and Jing Yang _

PDF | HTML | How to cite

Oncotarget. 2011; 2:562-568. https://doi.org/10.18632/oncotarget.301

Metrics: PDF 4354 views | HTML 4501 views | ?

Abstract

Mark A. Eckert^1,2 and Jing Yang^1,3

¹ Department of Pharmacology

² The Molecular Pathology Graduate Program

³ Department of Pediatrics

Received: June 30, 2011; Accepted: June 30, 2011; Published: June 30, 2011;

Keywords: Twist1, PDGFR, Src, MMP, MT1-MMP, SFK, metastasis, invasion, breast cancer, invadopodia, podosomes

Correspondence:

Jing Yang, email:

Abstract

Better understanding the mechanisms underlying the metastatic process is essential to developing novel targeted therapeutics. Recently, invadopodia have been increasingly recognized as important drivers of local invasion in metastasis. Invadopodia are basally-localized, actin-rich structures that concentrate protease activity to areas of the cell in contact with the extracellular matrix. We recently found that the transcription factor Twist1, a central regulator of the epithelial-mesenchymal transition (EMT), promotes invadopodia formation via upregulation of platelet-derived growth factor receptor (PDGFR) expression and activity. This finding, combined with other investigations into the mechanisms of invadopodia formation, reveal several novel targets for clinical inhibition of invadopodia. Here, we provide an overview of clinically-relevant targets for intervention in invadopodia, including Src signaling, PDGFR signaling, and metalloprotease activity.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 301

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Perspectives:

Targeting invadopodia to block breast cancer metastasis

Abstract